Realty Income Corp vs BIO-TECHNE Corp — how do they compare? Realty Income Corp trades at $54.12 (market cap $51.26B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Realty Income Corp is far larger — about 4.5× BIO-TECHNE Corp's market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and BIO-TECHNE Corp for 63 Days on average.
| O | TECH | |
|---|---|---|
Market Cap | $51.26B | $11.36B |
Volume | 12,300,266 | 5,390,331 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $72.61 |
52-Week Low | $53.35 | $43.31 |
Typical Hold Time | 127 Days | 63 Days |
Enterprise Value | $81.88B | $11.39B |
Dividend Yield | 6.01% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $53.35, down 1.66% amid bearish technical signals and recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though rising bond yields pressure valuations. Analyst consensus remains cautiously optimistic with a $64.80 price target despite three consecutive quarterly EPS misses.
The stock faces near-term headwinds from technical weakness and interest rate sensitivity, but long-term investors may find value in the 6%+ dividend yield and A-rated balance sheet. Key risks include persistent earnings underperformance and debt levels approaching 40% of assets, requiring careful monitoring of Q3 2026 results due November 2.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →